Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study
Authors:
Open Access
- 4 August 2017
- journal article
- research article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 53 (4) , 494-506
Abstract
Background Budesonide foam is used for the topical treatment of distal ulcerative colitis. This phase III study was performed to confirm mucosal healing and other therapeutic effects of twice-daily budesonide 2-mg foam in patients with mild-to-moderate ulcerative colitis including left-sided colitis and pancolitis. Methods This was a multicenter, randomized, placebo-controlled, double-blind trial. A total of 126 patients with mild-to-moderate ulcerative colitis with active inflammation in the distal colon were randomized to two groups receiving twice-daily budesonide 2 mg/25 ml foam or placebo foam. The primary endpoint was the percentage of complete mucosal healing of distal lesions (endoscopic subscore of 0) at week 6. Some patients continued the treatment through week 12. Drug efficacy and safety were evaluated. Results The percentages of both complete mucosal healing of distal lesions and clinical remission were significantly improved in the budesonide as compared with the placebo group (p = 0.0003 and p = 0.0035). Subgroup analysis showed similar efficacy of budesonide foam for complete mucosal healing of distal lesions and clinical remission regardless of disease type. The clinical remission percentage tended to be higher in patients achieving complete mucosal healing of distal lesions than in other patients. There were no safety concerns with budesonide foam. Conclusions This study confirmed for the first time complete mucosal healing with twice-daily budesonide 2-mg foam in mild-to-moderate ulcerative colitis with distal active inflammation. The results also indicated that complete mucosal healing of distal lesions by budesonide foam promotes clinical remission of ulcerative colitis. Clinical trial registration no.: Japic CTI-142704.Keywords
Funding Information
- EA Pharma Co., Ltd.
This publication has 26 references indexed in Scilit:
- Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative ColitisGastroenterology Research and Practice, 2013
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative ColitisGastroenterology, 2011
- Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis - additional results from two controlled studiesAlimentary Pharmacology & Therapeutics, 2011
- MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trialsAlimentary Pharmacology & Therapeutics, 2007
- Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditisAlimentary Pharmacology & Therapeutics, 2005
- Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitisAlimentary Pharmacology & Therapeutics, 2005
- Progression of ulcerative proctosigmoiditisEuropean Journal of Gastroenterology & Hepatology, 1996
- Changes in Extent of Ulcerative Colitis A Study on the Course and Prognostic FactorsScandinavian Journal of Gastroenterology, 1996
- Comparison of budesonide and 5‐aminosalicylic acid enemas in active distal ulcerative colitisAlimentary Pharmacology & Therapeutics, 1995
- Budesonide versus prednisolone retention enemas in active distal ulcerative colitisAlimentary Pharmacology & Therapeutics, 1994